---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-22-000015"
form_type: "8-K12B/A"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:36:58.893335+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho reports pro forma combined revenue of $2.4B and net income of $489.9M for H1 2022

## Summary
- Pro forma combined revenue for six months ended July 3, 2022: $2.4B; net income $489.9M; diluted EPS $7.22.
- Pro forma combined revenue for year ended Jan 2, 2022: $3.74B; net income $619.1M; diluted EPS $9.08.
- Acquisition of Ortho Clinical Diagnostics closed May 27, 2022; total purchase consideration ~$4.3B.
- Ortho shareholders received $7.14 cash + 0.1055 shares per Ortho share; $2.5B in stock and $1.75B cash paid.
- Preliminary purchase price allocation: $3.13B intangible assets, $2.29B goodwill, $767.5M PP&E.

## SEC filing metadata
- accession: 0001906324-22-000015
- form_type: 8-K12B/A
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632422000015/0001906324-22-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632422000015/qdel-20220527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-22-000015
- JSON: https://secwatch.observer/filing/0001906324-22-000015.json
- Plain text: https://secwatch.observer/filing/0001906324-22-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.